Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients.
Daniel P HurkmansMerian E KuipersJasper SmitRonald van MarionRon H J MathijssenPiet E PostmusPieter S HiemstraJoachim G J V AertsJan H von der ThüsenSjoerd H van der BurgPublished in: Cancer immunology, immunotherapy : CII (2020)
This proof-of-concept study suggests that a combination of PD-L1 expression, TML, CD8+ T cell infiltration and HLA class-I functions as a better predictive biomarker for response to anti-PD-1 immunotherapy. Consequently, refinement of this set of biomarkers and validation in a larger set of patients is warranted.